Rhumbline Advisers’ $2.5 Billion Healthcare Portfolio Owns These Stocks the Most: JNJ, PFE, MRK, ABT

Wall St. Watchdog reveals information regarding Rhumbline Advisers’ top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 327 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $2.588 billion.

  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, Rhumbline Advisers reported holding 4,858,102 shares with a market value of $323,160,929. This comprised 1.19% of the total portfolio. On 09/30/2011, Rhumbline Advisers reported holding 5,066,664 shares with a market value of $322,695,823. This comprised 1.35% of the total portfolio. The net change in shares for this position over the two quarters is 208,562. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, Rhumbline Advisers reported holding 13,564,023 shares with a market value of $279,418,879. This comprised 1.03% of the total portfolio. On 09/30/2011, Rhumbline Advisers reported holding 13,815,900 shares with a market value of $244,265,116. This comprised 1.02% of the total portfolio. The net change in shares for this position over the two quarters is 251,877. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, Rhumbline Advisers reported holding 5,353,737 shares with a market value of $188,933,384. This comprised 0.7% of the total portfolio. On 09/30/2011, Rhumbline Advisers reported holding 5,464,813 shares with a market value of $178,699,389. This comprised 0.75% of the total portfolio. The net change in shares for this position over the two quarters is 111,076. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Abbott Laboratories (NYSE:ABT): On 06/30/2011, Rhumbline Advisers reported holding 3,278,397 shares with a market value of $172,509,247. This comprised 0.63% of the total portfolio. On 09/30/2011, Rhumbline Advisers reported holding 3,426,006 shares with a market value of $175,205,945. This comprised 0.73% of the total portfolio. The net change in shares for this position over the two quarters is 147,609. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011, Rhumbline Advisers reported holding 1,765,583 shares with a market value of $103,021,765. This comprised 0.38% of the total portfolio. On 09/30/2011, Rhumbline Advisers reported holding 1,817,554 shares with a market value of $99,892,766. This comprised 0.42% of the total portfolio. The net change in shares for this position over the two quarters is 51,971. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011, Rhumbline Advisers reported holding 3,009,715 shares with a market value of $87,161,344. This comprised 0.32% of the total portfolio. On 09/30/2011, Rhumbline Advisers reported holding 3,139,015 shares with a market value of $98,502,288. This comprised 0.41% of the total portfolio. The net change in shares for this position over the two quarters is 129,300. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, Rhumbline Advisers reported holding 2,045,804 shares with a market value of $105,522,574. This comprised 0.39% of the total portfolio. On 09/30/2011, Rhumbline Advisers reported holding 2,084,745 shares with a market value of $96,148,437. This comprised 0.4% of the total portfolio. The net change in shares for this position over the two quarters is 38,941. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.
  • Medtronic Inc. (NYSE:MDT): On 06/30/2011, Rhumbline Advisers reported holding 2,198,093 shares with a market value of $84,692,521. This comprised 0.31% of the total portfolio. On 09/30/2011, Rhumbline Advisers reported holding 2,324,577 shares with a market value of $77,268,943. This comprised 0.32% of the total portfolio. The net change in shares for this position over the two quarters is 126,484. About Company: Medtronic, Inc. develops therapeutic and diagnostic medical products. The Company’s principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. Medtronic’s products are sold worldwide.
  • Eli Lilly & Co. (NYSE:LLY): On 06/30/2011, Rhumbline Advisers reported holding 1,857,545 shares with a market value of $69,713,662. This comprised 0.26% of the total portfolio. On 09/30/2011, Rhumbline Advisers reported holding 1,900,305 shares with a market value of $70,254,278. This comprised 0.29% of the total portfolio. The net change in shares for this position over the two quarters is 42,760. About Company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
  • Gilead Sciences Inc. (NASDAQ:GILD): On 06/30/2011, Rhumbline Advisers reported holding 1,686,470 shares with a market value of $69,836,722. This comprised 0.26% of the total portfolio. On 09/30/2011, Rhumbline Advisers reported holding 1,716,004 shares with a market value of $66,580,954. This comprised 0.28% of the total portfolio. The net change in shares for this position over the two quarters is 29,534. About Company: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

(Note: Data regarding Rhumbline Advisers’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>